NCT05249127View on ClinicalTrials.gov

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

August 8, 2023

Study Completion Date

August 8, 2023

Conditions
Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
DRUG

64Cu-SAR-bisPSMA

64Cu-SAR-bisPSMA

Trial Locations (5)

29572

Carolina Urologic Research Center, Myrtle Beach

68130

GU Research Network, Omaha

78258

Urology San Antonio, San Antonio

87109

New Mexico Cancer Center, Albuquerque

90048

Tower Urology, Los Angeles

Sponsors
All Listed Sponsors
lead

Clarity Pharmaceuticals Ltd

INDUSTRY